ViewRay, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRAY research report →
Range $4 – $8
Price Chart
About the company
ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom.
- CEO
- Paul Ziegler Jr.,
- IPO
- 2015
- Employees
- 295
- HQ
- Oakwood, OH, US
Get TickerSpark's AI analysis on VRAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.56M
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.51
- Div Yield
- 0.00%
- Gross Margin
- 9.83%
- Op Margin
- -104.81%
- Net Margin
- -105.01%
- ROE
- -85.17%
- ROIC
- -59.34%
Latest fiscal year · YoY change
- Revenue
- $102.21M+45.8%
- Gross Profit
- $10.04M+2898.5%
- Op Income
- $-107,127,000
- Net Income
- $-107,533,000-1.3%
- EPS
- $-0.60+7.7%
- OCF Growth
- -47.7%
- FCF Growth
- -50.2%
- 52W High
- $0.04
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 0.70
- RSI (14)
- 20
- Avg Volume
- 96.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ViewRay said first-quarter results were already preannounced, but the call underscored severe customer/payment headwinds, a strategic review, and a decision to suspend full-year guidance while cutting costs to preserve cash.· May 10, 2023
- Management is focused on a strategic review with Goldman and said it will not disclose details until the Board approves a transaction or action.
- ViewRay is cutting costs by $19 million to $23 million on a full-year run-rate basis, with about 65% of the savings expected in the current fiscal year.
- The company ended Q1 with about $85 million to $86 million in cash and said it has the runway to get through the process, but it would not give a new cash timeline.
- No backlog orders have been canceled, and management said it continues to discuss new and incremental systems with customers, though some are pausing until there is more clarity.
- A cost-down project targeting about $1 million out of cost of goods is still underway, with launch timing estimated for early 2026.
The call did not restate full quarter revenue, EPS, or gross margin figures; management said the quarter had already been preannounced. Scott Drake said ViewRay ended Q1 with about $85 million to $86 million in cash. The company also said it is reducing expenses by $19 million to $23 million on a full-year run-rate basis, with about 65% of that savings realized in the current fiscal year. Full-year guidance was suspended because of the strategic review and uncertainty around customer timing and installations.
Scott Drake framed the quarter around three priorities: the strategic process, cost and cash preservation, and guidance. He emphasized that ViewRay is working with Goldman on strategic alternatives and that the process could result in anything from a sale to a capitalization event, but he would not speculate on timing. His tone was cautious and defensive, repeatedly stressing that time is not on the company’s side, while also highlighting strong clinical momentum, a sizable backlog, and the importance of transparency with investors.
Jake Signoriello, in his first call as interim CFO, mainly reinforced the cash-preservation plan and the scale of the cost cuts. Management said the $19 million to $23 million reduction is an operating expense run-rate cut, not a working-capital measure, and that roughly 65% of the savings will show up in the current fiscal year. Scott also said the company ended Q1 with about $85 million to $86 million in cash, and management declined to discuss the SVB credit line or provide a new cash runway marker after suspending guidance.
Analysts focused on cash runway, the status of the SVB line of credit, backlog conversion, customer hesitation, and whether ViewRay might be seeing rising bad debts or write-offs. Management said no backlog orders had been canceled, receivables remain collectible, and there has been no change in the company’s bad-debt experience, though some customers are pausing decisions to see how the strategic review plays out. On the financing and construction headwinds, Scott said ViewRay has tried third-party financing, backlog monetization, and other working-capital relief efforts with only modest success, and that the company’s cost-down project is intended to reduce both cost of goods and installation burden.
The company said it still has a sizable backlog, no canceled orders, and ongoing interest from current and prospective customers, including at least one customer discussing a second system. Management also said the customer decision cycle is often long, so near-term hesitation may not mean demand has disappeared. If the strategic review leads to a recapitalization or sale, investors could see a cleaner balance sheet alongside the company’s MRIdian clinical positioning.
ViewRay is operating under severe uncertainty: distributors are paying more slowly, construction costs are delaying installations, and some customers are waiting for clarity before moving forward. Management suspended guidance, would not update cash runway beyond saying it has enough to get through the strategic process, and acknowledged that the sales organization has been affected. The company also said the cost-down project is not expected to launch until early 2026, leaving little near-term relief from current commercial and cash pressures.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 182.31M
- Float Shares
- 0
of shares held by institutions
189 13F filers
Buy/sell ratio 0.36. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VRAY, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parian Global Management LP | 265.00K | ▲ 265.00K |
| Telemetry Investments, L.L.C. | 200.00K | ▲ 10.00K |
| Jefferies Group LLC | 169.10K | ▲ 120.47K |
| Parametric Portfolio Associates LLC | 43.13K | ▼ 19.04K |
| Amalgamated Financial Corp. | 22.54K | ▲ 22.54K |
| B. Riley Wealth Management, Inc. | 11.50K | 0 |
| Wipfli Financial Advisors LLC, | 362 | ▲ 362 |
Held by 1 ETFs
Biggest fund positions in VRAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 23 | Shah Sanket | other | 350,000 |
| Jul 21, 23 | Shah Sanket | sell | 30,364 |
| Jul 15, 23 | Podbelski Adam Andrew | other | 350,000 |
| Jul 17, 23 | Podbelski Adam Andrew | sell | 89,901 |
| Jul 15, 23 | Shah Sanket | other | 0 |
| Jul 15, 23 | Shah Sanket | other | 30,000 |
| Jul 15, 23 | Shah Sanket | other | 31,773 |
| Jul 15, 23 | Podbelski Adam Andrew | other | 0 |
| Jul 15, 23 | Podbelski Adam Andrew | other | 24,000 |
| Jul 15, 23 | Podbelski Adam Andrew | other | 70,327 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRAY coverage
Recent articles, reports, and earnings notes.
No research on VRAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRAY report →Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology
businesswire.com · Oct 18
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
businesswire.com · Oct 17
Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
businesswire.com · Oct 13
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
prnewswire.com · Jul 21
Why Is ViewRay (VRAY) Stock Down 69% Today?
· Jul 17
ViewRay® Files Voluntary Chapter 11 Petitions
· Jul 17
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System
prnewswire.com · Jun 13
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
benzinga.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.